Completed PHASE1 INTERVENTIONAL NCT00025571

Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer

A Phase I Study of Photodynamic Therapy (PDT) Using 2-(1-hexyloxyethyl)-2 Devinyl Pyropheophorbide-a (HPPH) for Treatment of Early Stage Lung Cancer - A Dose Ranging Study

Sponsor: Roswell Park Cancer Institute

Conditions Lung Cancer

Interventions HPPH

Updated 6 times since 2017 Last updated: Mar 3, 2011 Started: Jun 30, 2001 Primary completion: Oct 31, 2002 Completion: Oct 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00025571, this PHASE1 trial focuses on Lung Cancer and remains completed. Sponsored by Roswell Park Cancer Institute, it has been updated 6 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jun 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Roswell Park Cancer Institute

Data source: Roswell Park Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Buffalo, United States